HomeInsightsStock Comparison

Bafna Pharmaceuticals Ltd vs Desh Rakshak Aushdhalaya Ltd Stock Comparison

Bafna Pharmaceuticals Ltd vs Desh Rakshak Aushdhalaya Ltd Stock Comparison

Last Updated on: May 07, 2026

Key Highlights

  • The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 132.65 as of 07 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 yearsThe P/E Ratio of Desh Rakshak Aushdhalaya Ltd changed from 4.5 on March 2021 to 29.5 on March 2025 . This represents a CAGR of 45.65% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 yearsThe Market Cap of Desh Rakshak Aushdhalaya Ltd changed from ₹ 1.82 crore on March 2021 to ₹ 13.38 crore on March 2025 . This represents a CAGR of 49.03% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 39.51 crore as compare to the Sep '25 revenue of ₹ 36.65 crore. This represent the growth of 7.8% The revenue of Desh Rakshak Aushdhalaya Ltd for the Dec '25 is ₹ 1.4 crore as compare to the Sep '25 revenue of ₹ 0.95 crore. This represent the growth of 47.37% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 4.27 crore as compare to the Sep '25 ebitda of ₹ 5.46 crore. This represent the decline of -21.79% The ebitda of Desh Rakshak Aushdhalaya Ltd for the Dec '25 is ₹ 0.25 crore as compare to the Sep '25 ebitda of ₹ 0.26 crore. This represent the decline of -3.85% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 1.84 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Desh Rakshak Aushdhalaya Ltd changed from ₹ 0.09 crore to ₹ 0.09 crore over 7 quarters. This represents a CAGR of 0.00% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Desh Rakshak Aushdhalaya Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

  • Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
  • The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
  • Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
  • During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Desh Rakshak Aushdhalaya Ltd

  • The flagship company Desh Rakshak Aushdhalaya Limited of Bhagwant Group was originally started in 1901 as a Proprietorship Concern by Late Shri Bhagwant Rai Jain, a well renowned Vaidya Father of Late Dr. Paras Kumar Jain.
  • The Concern was converted into a Private Limited Company in Jul.'94. Desh Rakshakare the oldest manufacturer of Pure Ayurvedic and Herbal Products as discovered by the Ancient Seers & Sages.
  • The medicines are categorized into Proprietary & Classical Medicines.
  • They are currently manufacturing around 450 products (Proprietary & Classical mix) and all of these medicines are manufactured as per the prescribed norms and standards of the Indian Government.
  • The Company was earlier operating the traditional process of manufacturing ayurvedic medicines. Up to 1976, the company producing ethical products of ayurvedic medicines which were supplied to ayurvedic dispensaries.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Desh Rakshak Aushdhalaya Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 313 Cr while Market cap of Desh Rakshak Aushdhalaya Ltd is 14 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd?

As of May 7, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹132.65. On the other hand, Desh Rakshak Aushdhalaya Ltd stock price is INR ₹24.8.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Desh Rakshak Aushdhalaya Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions